Boston Scientific's CEO Bought $9 Million in Stock Three Weeks Before the Cyberattack That Just Blew Up Guidance

The CEO bought $9 million in stock. Three weeks later, the company said it would miss its own guidance.

Michael F. Mahoney, the Chairman, President and CEO of Boston Scientific Corp ($BSX), spent $9.0 million buying 186,240 shares at a weighted average price of $48.33, in open market purchases on August 3 and 4, 2026. On September 8, Boston Scientific filed an 8-K saying a cyberattack first identified on August 25 is now expected to be big enough to blow through the net sales growth and adjusted EPS guidance it gave investors on July 29.

Read the two filings side by side and the question asks itself. Did the CEO know something was coming?

What actually happened

The August 25 incident disrupted Boston Scientific’s information systems and business applications, including its ability to process and ship customer orders, according to the company’s initial 8-K. The September 8 follow up filing goes further: the incident is “likely to have a material impact” on third quarter and full year 2026 results, and the company now says it is unlikely to hit the sales and adjusted profit forecast it issued on July 29. A full restoration timeline is still not known. An updated outlook is due on the October 28 earnings call.

NexusAlert’s Alerts feed flagged the update as High severity the same morning it hit EDGAR, tagged material impairment, with the AI summary and impact read already extracted before Bloomberg and Yahoo Finance had their versions online.

Was the timing suspicious? Probably not, and here is why

A cyberattack is not an event a company schedules. Unlike an earnings miss or a failed drug trial, nobody inside Boston Scientific chose August 25 as the day intruders would get in. That matters, because the entire premise of insider trading law is that an insider is acting on material information the company itself controls and has not yet disclosed. A CEO cannot have advance knowledge of an attack that has not happened yet.

So the honest read of Mahoney’s August 3 purchase is not “the CEO knew.” It is closer to the opposite. He put $9 million of his own money into the stock three weeks before a shock nobody could have priced in, which means he was making a real bet with real downside, not hedging one. That is a very different signal than an executive who sells right before a guidance cut they had a hand in writing.

The Dossier’s other data points

NexusAlert’s Company Dossier scores Mahoney’s Insider Conviction pillar at 10.0 out of 10, the strongest rating the platform gives, placing Boston Scientific in the top of every company scored. But conviction scores are not built on one transaction, and the rest of his 2026 filing history is worth sitting with. On February 2, Mahoney made a real discretionary sale of $14.9 million. On February 17, a separate Form 4 shows $9.9 million in shares withheld to cover taxes on vesting, a Code F transaction that is not a sale at all and should never be read as one.

Put together, this is not a CEO who only buys or only sells. He sold in February, when the stock was trading near its highs, and bought again in August, near a multi month low. That toggling between conviction and profit taking is a more believable pattern than a one way bet in either direction.

Company wide, Boston Scientific’s insider tape is net negative for the year: $22.0 million sold across 127 transactions, split between C-suite ($26.9 million sold), officers ($13.3 million), and directors ($1.3 million). Mahoney’s August purchase is the exception inside that tape, not the rule, which is exactly why NexusAlert’s platform flags a Strong conviction score even against a net selling year. NexusAlert’s own signal track record shows a median abnormal return of 2.5% across 517 comparable cases tracked since November 2025, a base rate worth knowing before treating any single filing as a prediction.

The bigger pattern

An insider buying with real money before bad news breaks is not proof of foreknowledge. It is proof he was willing to be publicly wrong. That distinction matters more than the headline guidance cut on its own, because a guidance cut tells you what happened to the business. A CEO’s own trades tell you what he believed about the business before he knew what was coming.

Read the whole filing, not just the headline number. A guidance cut reads differently once you have seen what the CEO was doing with his own money three weeks earlier, and a Form 4 sale reads differently once you know whether it is a discretionary bet or a tax withholding line the disposition code explains away.

Create a free NexusAlert account to see alerts like this one, and the Company Dossier behind them, the same day they hit EDGAR.

Sources

• Boston Scientific Unlikely to Meet Forecasts After Cyber Attack (Bloomberg)
• Boston Scientific says cyberattack will materially hit Q3, full year results (Seeking Alpha)
• Boston Scientific says cyberattack likely to hurt 2026 sales, profit (Yahoo Finance)
• Boston Scientific Corp Form 4, August 3, 2026 insider trading activity (StockTitan, SEC Form 4 filing detail)
• Boston Scientific Corp 8-K, cybersecurity incident, filed August 26, 2026 (SEC EDGAR)